Home
About us
Services
Clients
News-Events
Team
Contact
Strategic intelligence for the radiation healthcare
Bringing value to businesses and investors!
Events-Congresses
News-Events

Newsletters

Download our recent newsletters providing key facts about Nuclear Medicine, Proton Therapy and Brachytherapy.




News

March 2017
Proton therapy represents a niche, but growing, market

Article co-autored by Paul-Emmanuel Goethals and Dr. Richard Zimmermann, in DOTmed HealthCare Business News magazine, March 2017.
www.dotmed.com

...Read full story



March 15, 2017
Nuclear Medicine, Proton Therapy, Brachytherapy reports and directories

Over 1,900 pages of unbiased and factual intelligence from experts in nuclear medicine, cyclotrons, proton therapy and brachytherapy

...Read full story



January 27, 2017
MEDraysintell releases its Proton Therapy Market Essentials report 2017

MEDraysintell publishes its new “Proton Therapy Market Essentials” report providing key facts and figures on Proton Therapy to advice non-industry insiders on the potential for investments, market development, merger and acquisitions (M&A) existing in this healthcare technology.

...Read full story



January 18, 2017
MEDraysintell releases its first Nuclear Medicine Market Essentials report

MEDraysintell publishes its new “Nuclear Medicine Market Essentials” report providing key facts and figures on Nuclear Medicine to advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology.

...Read full story



November 30, 2016
MEDraysintell will launch its Market Essentials reports

MEDraysintell plans to launch early 2017 two new “Market Essentials Reports” providing key facts on Nuclear Medicine and Proton Therapy to advice non-industry insiders on the potential for investments, merger and acquisitions (M&A), technology and market development existing in healthcare technologies using radiation for diagnosis and therapy.

...Read full story



November 8, 2016
From Nuclear Medicine to Proton Therapy, opportunities for growth rising three times faster than the global healthcare

MEDraysintell sees an increasing interest from investors and industry as new technologies and products are being marketed or under development in nuclear medicine, brachytherapy and proton therapy.

...Read full story



October 7, 2016
Proton Therapy World Market is expanding faster

MEDraysintell releases the fourth edition of its Proton Therapy World Market Report and Directory, a 290-page document that provides a comprehensive review of the world market dynamics...

...Read full story



October 3, 2016
MEDraysintell to showcase its reports at EANM in Barcelona

MEDraysintell will display its series of market reports and directories with over 1,900 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the EANM – European Association of Nuclear Medicine – congress (Barcelona, Spain, October 16-18, 2016).

...Read full story



June 2016
Gallium-68, Lutetium-177, gain in the pharmaceutical world

Article co-autored by Paul-Emmanuel Goethals and Dr. Richard Zimmermann, in DOTmed HealthCare Business News magazine, June 2016.
www.dotmed.com

...Read full story



June 27, 2016
Nuclear Medicine World Market Report and Directory 2016

MEDraysintell considers 2016 to be the pivotal year for the nuclear medicine industry.
MEDraysintell releases its new Nuclear Medicine World Market Report and Directory–Edition 2016, a 990-page document that provides an exhaustive description and analysis of over 370 radiopharmaceuticals and radionuclides with a comprehensive profile of more than 170 companies and institutions active in the radiopharmaceuticals industry...

...Read full story



June 8, 2016
Nuclear Medicine Market: modest growth during the last two years

MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached US$ 4.3 billion in 2015, growing by just over 2% a year between 2013 and 2015. This slow growth is primarily driven by lower revenues from technetium-99m related products and an unfavorable impact from US$ exchange rates versus major currencies...

...Read full story



May 10, 2016
MEDraysintell to showcase its reports at SNMMI in San Diego

MEDraysintell will display its series of market reports and directories with over 1,800 pages of unrivaled intelligence covering Nuclear Medicine, Cyclotrons, Brachytherapy and Proton Therapy, during the SNMMI – Society of Nuclear Medicine and Molecular Imaging– congress (San Diego, CA, USA, June 11-15, 2016)...

...Read full story



March 23, 2016
Nuclear Medicine, a dynamic industry

The nuclear medicine industry has been very active in the recent months which can be highlighted through several key events, confirming the trend announced by MEDraysintell since two years which anticipated an increasing interest from investors and conventional pharmaceutical industries for the nuclear medicine market, mainly in the therapeutic area.

...Read full story



March 16, 2016
Brachytherapy market to growth by 8% to 2030, new vendors and new products to come

The global brachytherapy industry is evaluated in a new and updated MEDraysintell’s report and directory, providing in a 340-page document a complete description of the radionuclides and devices used in brachytherapy, and a detailed profile of 62 companies and institutions active in this field around the world.

...Read full story



January 27, 2016
Radioactivity used in medicine, a land of opportunities

Nuclear medicine, proton therapy and brachytherapy, some of the most exciting healthcare technologies using radiation for diagnosis and treatment, are niche markets but growing more than twice as fast as the global health market. 

...Read full story



January 6, 2016
Proton Therapy Sales Orders Reached Just Over US$ 1 Billion in 2015

Proton Therapy sales orders have more than doubled in 2015 compared to 2014.
MEDraysintell noticed that in 2015 the global proton therapy sales orders grew to record levels at just over US$ 1 billion for a total of 58 proton therapy treatment rooms.

...Read full story


 
December 3, 2015
MEDraysintell identifies more than 1,200 medical cyclotrons worldwide

MEDraysintell releases its new and unique report “Cyclotrons used in Nuclear Medicine, World Market Report & Directory, Edition 2015” that describes more than 1,200 medical cyclotrons worldwide.

...Read full story


 
November 17, 2015
Radiotherapeutics are driving up the nuclear medicine market

In the last few weeks two leading companies proved that radiotherapeutics are becoming the driving forces of the nuclear medicine market.

...Read full story


 
 
October 6, 2015
MEDraysintell to showcase its expert reports at EANM

MEDraysintell will display its series of market reports and directories on Nuclear Medicine, Proton Therapy and Brachytherapy, during the EANM –European Association of Nuclear Medicine– congress (Hamburg, Germany, October 11-13, 2015). http://eanm15.eanm.org/
Visitors are welcome in the Rad4Med.be pavilion booth #177/183/184.

...Read full story


 
June 25, 2015
Developments in Nuclear Medicine Analyzed in a New Exhaustive Report and Directory

MEDraysintell releases its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, which in a 920-page document is providing a description and analysis of 335 radiopharmaceuticals and radionuclides and 160 companies and institutions active in nuclear medicine.



May 5, 2015
Proton Therapy World Market expected to reach US$ 1 billion in 2019

Proton Therapy World Market is expected to reach US$ 1 billion in 2019 with 330 proton therapy rooms, and between US$ 3.5 to 6.6 billion by 2030, with 1,200 to 1,800 proton therapy treatment rooms available to patients worldwide.



February 27, 2015
Radiotherapeutics, the Driving Force of Nuclear Medicine

The first annual financial results of Xofigo (radium-223 dichloride) from Bayer – a product used in the treatment of prostate and bone cancers – are in line with the MEDraysintell analysis showing that the growth of nuclear medicine in the future will come through therapeutic radiopharmaceuticals (radiotherapeutics).



November 4, 2014
Brachytherapy Market Recovery to Reach US$ 2.4 Billion

MEDraysintell is publishing a new report on Opportunities in Brachytherapy.
Brachytherapy market trend is toward a growth driven by new technologies (electronic brachytherapy, microspheres), new indications for LDR (lung, liver) and new markets (Asia, South America).



October 9, 2014
MEDraysintell launches its quarterly newsletter

MEDraysintell is launching today its first quarterly newsletter, providing key facts about Nuclear Medicine, Proton Therapy and Brachytherapy.




May 20, 2014
MEDraysintell appears in l'Echo about its report in Nuclear Medicine
 
title: Nuclear Medicine opens the therapeutic field.



May 5, 2014
Nuclear Medicine: Growth will be driven by therapeutic products

The global Nuclear Medicine market is expected to reach US$ 24 billion (EUR 18 billion) in 2030, showing an annual average growth of 11%. This is mostly driven by the therapeutic radiopharmaceutical market, which is expected to annually increase by 30% between 2014 and 2030.
...
read full story


April 23, 2014
Proton Therapy: The Global Market Reached $630 million in 2013

MEDraysintell, the expert in strategic intelligence for the medical radiation industry, publishes today a white paper providing some information about the global Proton Therapy market in 2013-2014.
...
read full story

March 13, 2014
World Nuclear Medicine: Opportunities are ahead!

MEDraysintell, the expert in strategic intelligence for the medical radiation industry, publishes its new report on Opportunities in Nuclear Medicine Edition 2014. Opportunities for developments, mergers and acquisitions, and investments are just ahead.
...
read full story




HomeAbout usServicesClientsNews-EventsTeamContact
© 2017 MEDraysintell